Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2000

View Archived Issues

Extensive review of novel cytoprotectant appears in supplementary issue of DOT

NCI initiates third phase II trial of O6-benzylguanine in combination with BCNU

Pharming and Baxter to jointly develop treatment for hereditary angioedema

Carrington Laboratories discontinues development of Aliminase due to disappointing phase III results

Incyte Pharmaceuticals to change name to Incyte Genomics

Merck & Co. confirms study results of Singulair as allergic rhinitis treatment

Oxford BioMedica enters agreement with Nycomed Amersham for tumor imaging

Novel CRF antagonists under study at DuPont

3-Dimensional Pharmaceuticals begins clinical testing of oral thrombin inhibitor

New metabotropic glutamate receptor agonists for psychiatric, neurological disorders

Positive preliminary results reported for Enzo's phase I trial of EHT-899

UCB's new muscarinic agents useful for pain, schizophrenia and Alzheimer's disease

New series from SB interacts with signal transduction to inhibit inflammation

Novel gastric antisecretory agents designed by AstraZeneca scientists

Kinetek validates ILK inhibition as potential cancer therapy

BMS patents new antibacterial series useful against resistant infections

Highly potent and orally bioavailable nonbenzamidine factor Xa inhibitors presented to ACS

Cangene begins pivotal HBV study, terminates agreement with Octapharma

ACS news: BMS presents potent new inhibitor of cyclin-dependent kinases

SR-10204 and SR-10208 identified as potent anti-HCMV agents

Discovery of ischemia-selective NMDA antagonists reported at ACS by Cambridge NeuroScience

Salix receives FDA approvable letter for balsalazide disodium

Two studies presented in Yokohama explore effects of GA-0113 in pulmonary hypertension

The FDA approves Zonegran for the treatment of epilepsy

TRK-820 demonstrates kappa-receptor-mediated antipruritic effects in animal model

FK-960, a novel antidementia agent in phase II, increases synapse density in aged rats

New farnesyltransferase inhibitor L-779575 presented by Merck this week

R.W. Johnson presents R&D on nicotinic acetylcholine receptor ligands